Sign in

    Timur Ivannikov

    biotech analyst at Raymond James

    Timur Ivannikov is a biotech analyst at Raymond James specializing in biotechnology and health innovation, where he actively covers companies including NexImmune, Crescent Biopharma, and Gyre Therapeutics. Known for his research coverage on eight technology and biotech stocks, Ivannikov has a recent TipRanks rating of 0.14 stars with a published 20% success rate, reflecting a disciplined, data-driven approach to investment calls. He previously held an analyst role at Cantor Fitzgerald, where he provided coverage and ratings for firms such as ProQR Therapeutics, before joining Raymond James in his current capacity. Ivannikov maintains professional credentials through FINRA registration and securities licenses in the research analyst category.

    Timur Ivannikov's questions to Apellis Pharmaceuticals (APLS) leadership

    Timur Ivannikov's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Timur Ivannikov, on for Steve Seedhouse at Cantor Fitzgerald, asked about the factors that led to higher Cyfovri revenue despite similar commercial doses quarter-over-quarter, and requested a breakdown of the 13,000 free injections between new patient samples and existing patient assistance.

    Answer

    EVP & Head of Global Commercial David Acheson explained that less than half of the growth was attributed to free goods/samples. He reiterated that demand is strong and growing, with patients starting on product through both commercial and free goods channels, including sampling and patient assistance programs.

    Ask Fintool Equity Research AI

    Timur Ivannikov's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Timur Ivannikov, for Steve Seedhouse at Cantor Fitzgerald, inquired about the factors that led to higher Cyfovri revenue despite similar commercial dose numbers quarter-over-quarter, and asked for a breakdown of the 13,000 free injections between new patient samples and existing patient assistance.

    Answer

    EVP of Commercial David Acheson clarified that a little less than half of the growth was attributable to free goods. He emphasized that overall demand is strong and growing quarter-over-quarter, with patient starts occurring through both commercial channels and the free goods programs.

    Ask Fintool Equity Research AI

    Timur Ivannikov's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Timur Ivannikov from Cantor Fitzgerald asked about the factors that led to higher Cyfovri revenue despite similar commercial doses quarter-over-quarter, and requested a breakdown of the 13,000 free injections between new patient samples and existing patient assistance.

    Answer

    EVP & Head of Global Commercial David Acheson stated that a little less than half of the growth was attributed to free goods/samples. He emphasized that there is true demand growth, with patients starting on product through both commercial channels and assistance programs, leading to the overall quarter-over-quarter growth.

    Ask Fintool Equity Research AI

    Timur Ivannikov's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Timur Ivannikov from Cantor Fitzgerald inquired about the factors that led to higher Cyfovri revenue despite similar commercial dose volumes quarter-over-quarter. He also asked for a breakdown of the 13,000 free injections between new patient samples and assistance for existing patients.

    Answer

    EVP of Commercial, David Acheson, attributed a little less than half of the growth to free goods and samples. He emphasized that underlying demand from physicians and patients is strong and continues to grow, with new patients starting on therapy through both commercial and patient assistance channels.

    Ask Fintool Equity Research AI

    Timur Ivannikov's questions to Mirum Pharmaceuticals (MIRM) leadership

    Timur Ivannikov's questions to Mirum Pharmaceuticals (MIRM) leadership • Q3 2024

    Question

    Timur Ivannikov, on for Steve Seedhouse, asked about the Fragile X program, specifically inquiring about plans to enroll patients younger than 18 and if the company could quantify how much more CNS activity its molecule might achieve compared to competitors.

    Answer

    Chief Medical Officer Joanne M. Quan stated that the clinical plan is to start with adult patients and then step down in age, which is a typical approach. While she could not quantify the exact increase in CNS activity, she reiterated that MRM-3379's brain-to-plasma ratio is 'quite a bit higher' than the competitor's, which they believe is a significant differentiating advantage.

    Ask Fintool Equity Research AI

    Timur Ivannikov's questions to Galmed Pharmaceuticals (GLMD) leadership

    Timur Ivannikov's questions to Galmed Pharmaceuticals (GLMD) leadership • Q2 2021

    Question

    Timur Ivannikov from Raymond James questioned the primary gating factors for starting the randomized Phase 3 study, the data benchmarks required from the open-label portion, the cadence of future data releases, and sought clarification on the development plan and formulation for Amilo-5MER.

    Answer

    President and CEO Allen Baharaff explained that a strong efficacy signal from the open-label data is a key gating item to de-risk the program, and they may wait for data from more than the initial 50 patients if needed. He confirmed the next cohort's data is expected in Q2 2022. For Amilo-5MER, he clarified that the Phase 1a study was subcutaneous and that the company is now developing both an oral, locally-acting formulation for ulcerative colitis and an injectable formulation for other indications like RA.

    Ask Fintool Equity Research AI

    Timur Ivannikov's questions to Galmed Pharmaceuticals (GLMD) leadership • Q2 2021

    Question

    Timur Ivannikov of Raymond James, on for Steve Seedhouse, asked about the primary gating factors for initiating the randomized Phase III study, the specific data benchmarks required from the open-label Aramchol data before proceeding, and the expected cadence of additional data cohorts from the open-label study.

    Answer

    Executive Allen Baharaff explained that the company must see a sufficiently strong signal from the open-label data to ensure a competitive product profile before launching the large, double-blind study, and they may wait for data from 100-150 patients if the first 50 is not enough. Chief Scientific Officer Liat Hayardeny noted the formulation development and data readout timelines are designed to intersect. Allen Baharaff confirmed the next data cohort, bringing the total to 100 patients, is expected in Q2 2022.

    Ask Fintool Equity Research AI

    Timur Ivannikov's questions to InflaRx (IFRX) leadership

    Timur Ivannikov's questions to InflaRx (IFRX) leadership • Q3 2019

    Question

    Timur Ivannikov of Raymond James sought clarification on whether the SHINE trial was considered underpowered, underdosed, or both, and if the company would consider another Phase II study. He also asked about the unblinding procedure and the reasons why 21 patients did not enter the open-label extension (OLE).

    Answer

    Executive Niels Riedemann stated the trial was underpowered to show a meaningful difference on the HiSCR endpoint with only 36 patients per group, given the score's high variability. He confirmed patients were not unblinded when transitioning to the OLE. He explained that the 21 patients who did not enter the OLE discontinued for a wide array of normal reasons, not a single common theme. The path forward, whether a Phase II or III trial, depends on regulatory feedback.

    Ask Fintool Equity Research AI